Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Everyone wants to kill generic drug loophole — except drug makers and some GOP leaders

By Christopher Rowland GLOBE STAFF MARCH 19, 2018

In recent years brand-name drug makers realized they could block generic competition by refusing to sell samples of their products to companies that wanted to make the lower-cost copies. All they had to do was cite safety rules that restrict sales of certain drugs with dangerous side effects.

“If they say no, we can’t move forward,’’ said Bruce A. Leicher, senior vice president and general counsel at Momenta Pharmaceuticals, a Cambridge company that is developing “biosimilars,’’ which are generic copies of costly biotechnolgy drugs. “It’s a perfect way to block development of competitive, affordable products.’’

Read more:
https://www.bostonglobe.com/news/nation/2018/03/19/congress-won-stop-drug-companies-who-use-shenanigans-block-generics/SOnAziaeVLhIvGvyX5BYkN/story.html